{
    "nct_id": "NCT04254978",
    "official_title": "A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia",
    "inclusion_criteria": "* Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.\n* Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.\n* Have failed at least one standard therapy\n* Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.\n* Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).\n* Uncontrolled active infection.\n* Current use of prohibited medications\n* Known HIV infection or active Hepatitis B or Hepatitis C virus infection\n* Other hematologic/biochemistry requirements, as per protocol\n* Use of investigational agent within last 14 days\n* Pregnant or lactating females",
    "miscellaneous_criteria": ""
}